Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

CHC Healthcare Group: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

30 Jan 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - CHC Healthcare Group (4164-TW)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

05 Feb 2016 Thomson Reuters Stock Report 11 $25.00

Wright Investors Service Comprehensive Report for CHC Healthcare Group

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

14 Jan 2016 Wright Reports 55 $75.00

CHC Healthcare Group: Upgraded to Average

21 Dec 2015 Sadif Analytics Prime 3 $10.00

CHC Healthcare Group: Downgraded to Below Average

01 Sep 2015 Sadif Analytics Prime 3 $10.00

CHC Healthcare Group (4164 TT): Substantial Growth in Radiotherapy Equipment Market in China

We forecast CHC’s FY14 sales of NT$2.46bn, +19% YoY, with growth momentum from the following. (1) Sales volume of radiotherap...

06 Jul 2014 MasterLink Securities Corporation 6 $58.00

承業醫(4164):中國放射腫瘤設備滲透率低,承業醫為主要受惠者

預估承業醫2014年營收24.6億元,YOY +19%,成長動能來自(1)2014年中國放射腫瘤儀器銷售量成長200%,(2) 4Q13取得GE電腦斷層與核磁共振之獨家代理,2014年可貢獻營收2億元,預估承業醫2014年EPS 3.18元;預估20...

30 Jun 2014 MasterLink Securities Corporation 5 $35.00

承業醫(4164):聽見中國好聲音

投資建議買進:元富預估2013年EPS 2.79元,2014年考量中國市場放射腫瘤治療機銷售不確定性較大,以及租賃合約通常6~12月後才有顯著貢獻,目前2014年中國營收獲利貢獻預估值僅包含1H14可望認列之一台直線加速器,稅後EPS即達3.82元,...

15 Nov 2013 MasterLink Securities Corporation 2 $23.00

CHC Healthcare Group (4164 TT): To Enjoy Long-term Growth Momentum

CHC announced distribution of IBA’s proton therapy equipment; its first client is Changhua Christian Hospital (CCH). If CHC s...

01 Nov 2012 MasterLink Securities Corporation 4 $35.00

承業(4164):長期獲利動能佳

承業近期已與全球最大質子治療設備大廠IBA簽約代理,首家合作醫院為彰化基督教醫院。元富推估,若以賣斷模式銷售,2012年底前將可認列第一筆頭期款約2.4億元,將貢獻EPS 0.2元。承業取得IBA代理權後,目前國內已有多家醫院正積極洽談中,目前公司推...

29 Oct 2012 MasterLink Securities Corporation 3 $12.00